July 10, 2012

260 East Grand Avenue
South San Francisco, CA 94080

Jeff Cooper Joins KaloBios as Chief Financial Officer

SOUTH SAN FRANCISCO, CA (July 10, 2012) - KaloBios Pharmaceuticals, Inc. KaloBios Pharmaceuticals, Inc. today announced the appointment of Jeffrey H. Cooper as Chief Financial Officer. Mr. Cooper was previously Senior Vice President and Chief Financial Officer of BioMarin Pharmaceutical, Inc., a publicly traded pharmaceutical company.

“Jeff Cooper is a senior finance executive and dynamic business leader with over 25 years of experience in the life sciences industry at both development-stage and multi-national companies,” said David W. Pritchard, KaloBios President and Chief Executive Officer. “At BioMarin, he was instrumental in helping to grow the company into a successful firm with a market capitalization exceeding $4 billion with operations around the globe and an outstanding financing track record. His noteworthy success as a leading financial executive in an orphan drug company that sells and develops biologics should serve KaloBios well as we realize the potential of our novel patient-targeted antibody therapeutics and the company enters its next phase of growth.”

“KaloBios offers a unique opportunity as a biotechnology company with unique technology, a promising pipeline of clinical-stage product candidates, and an experienced management team,” said Mr. Cooper. “I look forward to working with them to help realize the full potential of KaloBios’ business strategy and prospects.”

At BioMarin, Mr. Cooper started in 2003 as Vice President, Controller, and then served as its Chief Financial Officer from 2005 to May 2012. During his tenure as Chief Financial Officer at BioMarin, the company’s market capitalization increased more than sevenfold. Prior to BioMarin, from 1995 to 1997 and 1998 to 2002, he served as Vice President of Finance at Matrix Pharmaceuticals where he was responsible for the financial management of the company. Earlier in his career, Mr. Cooper held numerous finance-related positions within the health care and pharmaceutical industries, including Corporate Controller at Foundation Health Systems and Director of Business Analysis at Syntex Corporation, a company he worked for from 1983 to 1995. Mr. Cooper, a Certified Public Accountant (inactive), earned a Bachelor of Arts in economics from the University of California, Los Angeles, and a Master of Business Administration from Santa Clara University.

About KaloBios

KaloBios Pharmaceuticals, Inc., a South San Francisco, California based private company, is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.

Currently, KaloBios has three Investigational New Drug development programs:

• KB001-A, an anti-PcrV mAb fragment, is partnered with Sanofi Pasteur and is being developed for the treatment and prevention of Pseudomonas aeruginosa (Pa) infection.   KaloBios retained rights to cystic fibrosis and plans to initiate a Phase 2 study in patients with chronic Pa infection.
• KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases is being developed for the treatment of asthma.  KaloBios plans to initiate a Phase 2 study in asthma uncontrolled by corticosteroids.
• KB004,  a mAb targeting the EphA3 tyrosine kinase receptor, has potential utility in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in hematologic malignancies.

 
All our antibodies were generated using our proprietary Humaneered™ technology, a method that converts nonhuman antibodies (typically mouse) into engineered, human antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use.  We believe that antibodies produced with our Humaneered™ technology offer important clinical and economic advantages over antibodies generated by other methods, in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration.

For more information, visit http://www.kalobios.com.